[1] LEADER A M,GROUT J A,MAIER B B,et al.Single-cell analysis of human non-small cell lung cancer lesions refines tumor classification and patient stratification[J].Cancer Cell,2021,39(12):1594-1609.e12.
[2] RECK M,REMON J,HELLMANN M D.First-line immunotherapy for non-small-cell lung cancer[J].J Clin Oncol,2022,40(6):586-597.
[3] ETTINGER D S,WOOD D E,AISNER D L,et al.Non-Small Cell Lung Cancer,Version 3.2022,NCCN Clinical Practice Guidelines in Oncology[J].J Natl Compr Canc Netw,2022,20(5):497-530.
[4] 国家癌症中心,国家肿瘤质控中心肺癌质控专家委员会.中国原发性肺癌规范诊疗质量控制指标(2022版)[J].中华肿瘤杂志,2022,44(7):594-599.
[5] FORDE P M,SPICER J,LU S,et al.Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer[J].N Engl J Med,2022,386(21):1973-1985.
[6] SUN C,MEZZADRA R,SCHUMACHER T N.Regulation and function of the PD-L1 checkpoint[J].Immunity,2018,48(3):434-452.
[7] WU S Y,FU T,JIANG Y Z,et al.Natural killer cells in cancer biology and therapy[J].Mol Cancer,2020,19(1):120.
[8] 中华人民共和国国家卫生健康委员会.原发性肺癌诊疗规范(2018年版)[EB/OL].[2018-12-21].http://www.nhc.gov.cn/yzygj/s7659/201812/b21802b199814ab7b1219b87de0cae51.shtml
[9] 周彩存,王洁,王宝成,等.中国非小细胞肺癌免疫检查点抑制剂治疗专家共识(2020年版)[J].中国肺癌杂志,2021,24(4):217-235.
[10] EISENHAUER E A,THERASSE P,BOGAERTS J,et al.New response evaluation criteria in solid tumours:revised RECIST guideline(version 1.1)[J].Eur J Cancer,2009,45(2):228-247.
[11] BODOR J N,BOUMBER Y,BORGHAEI H.Biomarkers for immune checkpoint inhibition in non-small cell lung cancer(NSCLC)[J].Cancer,2020,126(2):260-270.
[12] PENG L,WANG Y,LIU F,et al.Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors[J].Cancer Immunol Immun,2020,69(9):1813-1822.
[13] NELLI F,PANICHI V,FABBRI A,et al.Dynamic changes of peripheral NK cells predict outcome in patients with PD-L1 positive non-small-cell lung cancer undergoing immune checkpoint inhibitors as second-line therapy[J].Cancer Invest,2022,40(8):710-721.
[14] DINGEMANS A C,HENDRIKS L,BERGHMANS T,et al.Definition of synchronous oligometastatic non-small cell lung cancer-a consensus report[J].J Thorac Oncol,2019,14(12):2109-2119.
[15] HUANG Z,FU Z,HUANG W,et al.Prognostic value of neutrophil-to-lymphocyte ratio in sepsis:a meta-analysis[J].Am J Emerg Med,2020,38(3):641-647.
[16] ZAHOREC R.Neutrophil-to-lymphocyte ratio,past,present and future perspectives[J].Bratisl Lek Listy,2021,122(7):474-488.
[17] 夏经纬,陈羽中,温少迪,等.外周血炎症指标作为预测性指标在晚期非小细胞肺癌免疫治疗中的应用[J].中国肺癌杂志,2021,24(9):632-645.
[18] CHRISTOFORI G.New signals from the invasive front[J].Nature,2006,441(7092):444-450.
[19] SHI J,HOU S,FANG Q,et al.PD-1 controls follicular T helper cell positioning and function[J].Immunity,2018,49(2):264-274.e4.
[20] 顾丽琴,濮阳隆翔,谢芳.PD-1/PD-L1参与NK细胞调控抗肿瘤免疫的作用机制[J].临床与实验病理学杂志,2022,38(4):452-455.
[21] HSU J,HODGINS J J,MARATHE M,et al.Contribution of NK cells to immunotherapy mediated by PD-1/PD-L1 blockade[J].J Clin Invest,2018,128(10):4654-4668.
[22] KIM N,KIM H S.Targeting checkpoint receptors and molecules for therapeutic modulation of natural killer cells[J].Front Immunol,2018,9:2041.
[23] 国家卫生健康委办公厅.原发性肺癌诊疗指南(2022年版)[J].协和医学杂志,2022,13(4):549-570. |